MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-08-2022
ChemoCentryx Revenue 2011-2026 | CCXI
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue ChemoCentryx
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 32.2 M | 64.9 M | 36 M | 42.9 M | 82.5 M | 11.4 M | - | - | 6.06 M | 5.42 M | 31.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 82.5 M | 5.42 M | 34.8 M |
Quarterly Revenue ChemoCentryx
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 11.8 M | 5.46 M | 2.32 M | 17.7 M | 1.81 M | 10.4 M | 4.36 M | 5.08 M | 49.4 M | 6.01 M | 10 M | 10.6 M | 7.17 M | 8.33 M | 9.33 M | 8.98 M | 15 M | 9.55 M | 56.3 M | 9.03 M | 8.94 M | 8.23 M | 4.89 M | 4.25 M | 2.8 M | - | - | - | - | - | - | - | - | - | 725 K | 1.52 M | 1.89 M | 1.93 M | 2.14 M | 1.13 M | 1.13 M | 1.02 M | 26.1 M | 1.44 M | 1.23 M | 2.95 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 56.3 M | 725 K | 8.94 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Apellis Pharmaceuticals
APLS
|
1 B | $ 20.16 | -2.61 % | $ 2.54 B |  USA |
 |
Aptorum Group Limited
APM
|
912 K | $ 0.79 | -6.17 % | $ 4.31 M |  China |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | USA |
 |
AbCellera Biologics
ABCL
|
75.1 M | $ 3.71 | -2.88 % | $ 1.11 B |  Canada |
 |
Athersys
ATHX
|
5.51 M | - | 3.77 % | $ 22.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
42.3 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
638 M | $ 164.05 | -1.4 % | $ 8.16 B | USA |
 |
BioDelivery Sciences International
BDSI
|
167 M | - | -4.8 % | $ 255 M | USA |
 |
Burford Capital Limited
BUR
|
330 M | $ 8.55 | -2.06 % | $ 1.39 B | Britain |
 |
BridgeBio Pharma
BBIO
|
502 M | $ 64.53 | -1.48 % | $ 12.4 B | USA |
 |
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | USA |
 |
CymaBay Therapeutics
CBAY
|
31.1 M | - | - | $ 3.45 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
140 M | - | - | $ 789 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
3.22 B | $ 58.53 | -2.03 % | $ 11.2 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
41 K | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
1 M | - | -16.75 % | $ 25.8 M | USA |
 |
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | USA |
 |
Clovis Oncology
CLVS
|
149 M | - | -7.23 % | $ 13 M | USA |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M | Canada |
 |
CTI BioPharma Corp.
CTIC
|
53.9 M | - | - | $ 1.2 B | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
43 K | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
43 K | - | -4.36 % | $ 27 M | USA |
 |
Cabaletta Bio
CABA
|
0.006 | $ 3.25 | -1.52 % | $ 3.8 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
163 M | - | - | $ 2.18 B | USA |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
Capricor Therapeutics
CAPR
|
25.2 M | $ 25.84 | -3.8 % | $ 692 M | USA |
 |
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
142 K | - | -10.17 % | $ 12.2 K | USA |
 |
Codexis
CDXS
|
59.3 M | $ 0.98 | -3.92 % | $ 71.9 M | USA |
 |
Certara
CERT
|
419 M | $ 7.24 | 2.7 % | $ 1.16 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
7 M | - | - | $ 105 M | USA |
 |
Evofem Biosciences
EVFM
|
18.2 M | - | 7.55 % | $ 38.1 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
Coherus BioSciences
CHRS
|
257 M | $ 1.65 | - | $ 155 M | USA |